Dermata Therapeutics, Inc.

DRMA

$1.23

+0.16%

2026-09-04 09:52:24 EDT+$0.00

Healthcare

Biotechnology

NASDAQ

Active Trading

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer ...

Key Metrics of DRMA

Snapshot

Latest / TTM · 6 periods

Market Cap

$838,315.00

ROCE

-246.6%

EV / EBITDA

0.42x

-121.7% YoY

FCF Yield

-971.6%

-610.6% YoY

Cash Conversion Cycle

0.0d

Current Ratio

2.81

Quick take

TTM —

No major risk flags in selected headline metrics.

Key Metrics

Latest / TTM · 6 periods

Valuation trend

Valuation trend table

Metric	2021	2022	2023	2024	2025	TTM
Market CapTotal market value of all shares outstanding.	$217.37M	$4.52M	$1.78M	$2.07M	$2.15M	$838,315
Enterprise ValueCompany value including debt and cash adjustments.	$206.57M	$-1.72M	$-5.66M	$-1.10M	$-5.37M	$-3.57M
EV / SalesHow many dollars investors pay per dollar of sales.	0.00x	0.00x	0.00x	0.00x	0.00x	0.00x
EV / EBITDAValuation multiple versus operating earnings before non-cash charges.	-26.29x	0.18x	-22.91x	0.09x	0.69x	0.42x
Net Debt / EBITDALeverage ratio using net debt divided by EBITDA.	1.37	0.65	-30.09	0.26	0.97	0.52

Returns + ROCE gauge

ROCE latest

-246.6%

Prev year -124.9%

Returns + ROCE gauge table

Metric	2021	2022	2023	2024	2025	TTM
ROEProfit generated from shareholders' equity.	-78.2%	-159.6%	-122.7%	-787.1%	-121.5%	-166.7%
ROAProfit generated from total assets.	-68.0%	-138.4%	-97.7%	-347.7%	-96.1%	-157.3%
ROICReturn generated on invested operating capital.	-77.7%	-160.7%	-122.7%	-787.1%	-124.9%	-245.8%
ROCEOperating return on long-term capital used.	-77.7%	-160.7%	-126.5%	-801.6%	-124.9%	-246.6%
Earnings YieldEarnings as a percentage of market value.	-3.6%	-212.7%	-439.1%	-594.9%	-351.8%	-169.2%

Cash flow quality

Cash flow quality table

Metric	2021	2022	2023	2024	2025	TTM
FCFFCash flow available to all capital providers.	$-5.65M	$-8.83M	$-6.41M	$-11.16M	$-7.76M	$-8.14M
FCFECash flow available to equity holders after debt flows.	$-4.69M	$-8.83M	$-6.41M	$-11.16M	$-7.76M	$-8.14M
FCF YieldFree cash flow divided by market capitalization.	-2.6%	-195.5%	-361.0%	-540.4%	-361.0%	-971.6%
Income QualityHow well accounting earnings are backed by cash flow.	0.72	0.92	0.82	0.91	1.03	0.96
Capex / OCFShare of operating cash flow spent on capital expenditures.	0.0%	-0.0%	0.0%	0.0%	0.0%	-1.4%

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	TTM
DSOAverage days to collect cash from customers.	0.0d	0.0d	0.0d	0.0d	0.0d	0.0d
DIOAverage days inventory stays before being sold.	0.0d	0.0d	0.0d	0.0d	0.0d	0.0d
DPOAverage days the company takes to pay suppliers.	0.0d	0.0d	0.0d	0.0d	0.0d	0.0d
Operating CycleTime from buying inventory to collecting receivables.	0.0d	0.0d	0.0d	0.0d	0.0d	0.0d
Cash Conversion CycleNet days cash is tied in operations.	0.0d	0.0d	0.0d	0.0d	0.0d	0.0d

Snapshot

Latest / TTM: —

Market Cap

$838,315

ROE

-166.7%

FCF Yield

-971.6%

Current Ratio

2.81

Supply Chain of DRMA

Upstream / Downstream / Proxies

Upstream

Reka-Farm LLCCrown Laboratories (formerly Revance Therapeutics)UnconfirmedTopical Formulation CDMO (Undisclosed)Cosmetic Contract Manufacturer (Tome Skincare)Volga River Delta Sponge HarvestersActive Pharmaceutical Ingredient (API) SuppliersPackaging & Component Suppliers

Downstream

Crown Laboratories (fka Revance Therapeutics)Direct-to-Consumer (DTC) Channel - Tome SkincarePotential XYNGARI Commercial Partner (Undisclosed)

Proxies

Botanix Pharmaceuticals LimitedASX:BOTSol-Gel Technologies Ltd.NASDAQ:SLGL Arcutis Biotherapeutics, Inc.NASDAQ:ARQT

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer